-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Autolus Therapeutics, Raises Price Target to $11

Benzinga·12/29/2025 12:26:14
Listen to the news
Needham analyst Gil Blum maintains Autolus Therapeutics (NASDAQ:AUTL) with a Buy and raises the price target from $10 to $11.